Proteostasis Therapeutics Expands Management Team with Two Strategic Positions

  Proteostasis Therapeutics Expands Management Team with Two Strategic

  - Company adds CMO and Senior Vice President of Chemistry leading into two
                  anticipated IND filings in 2014 and 2015 -

Business Wire

CAMBRIDGE, Mass. -- November 02, 2012

Proteostasis Therapeutics, Inc., a company developing novel therapeutics that
regulate protein homeostasis to improve outcomes for patients with
neurodegenerative and orphan diseases, announced today that two new senior
executives have joined the Company’s management team. Proteostasis has
appointed David Weiner, M.D., as Chief Medical Officer and Markus Haeberlein,
MSc, Ph.D., as Senior Vice President of Chemistry.

“Dave and Markus bring a wealth of research and development experience to our
company and will play pivotal roles as we move our lead clinical candidates
into IND filings in 2014 and 2015. I am pleased to welcome them to our
management team,” commented Mark Enyedy, Chief Executive Officer. “Dave will
formulate and execute the development and regulatory strategy for our current
pipeline as well as identify potential in-licensing opportunities to support
our overall corporate growth strategy. Markus will lead our efforts to
identify and optimize leads that modulate key pathways within the Proteostasis
Network to strengthen and diversify our pipeline.”

David Weiner, M.D., brings more than 20 years of industry and professional
medical experience to Proteostasis Therapeutics. Prior to joining the Company,
Dr. Weiner served in key development roles over a five-year period at EMD
Serono, Inc., most recently as Vice President and Head of Early Clinical
Development, Neurodegenerative Diseases. Before joining EMD Serono, Dr. Weiner
spent almost a decade at ACADIA Pharmaceuticals Inc., in both research and
clinical development positions, including Principal Scientist/Group Leader for
Target Validation and Medical Director. Dr. Weiner’s clinical experience
includes faculty appointments in Neuroscience and Psychiatry at the University
of California, San Diego, and the Departments of Neurology and Psychiatry at
the University of Vermont. He trained in Neurology at New York Hospital,
Memorial Sloan-Kettering Hospital, and Cornell Medical Center after completing
a Medical Internship at St. Vincent’s Hospital & Medical Center in New York,
and receiving his M.D. from the School of Medicine and Biomedical Sciences,
SUNY at Buffalo. Dr. Weiner also serves on the Scientific Advisory Board of
the Michael J. Fox Foundation.

Markus Haeberlein, MSc, Ph.D., spent 15 years at AstraZeneca in positions of
increasing responsibility, most recently as Director, Head of Medicinal
Chemistry, CNS and Pain IMed, where he oversaw more than 100 scientists and
contributed to over 15 neurology and pain drug candidates as well as novel PET
ligands for Alzheimer’s disease. Starting in 2009, he was also Chair of
AstraZeneca’s Global Chemistry Network, overseeing all global chemistry
activities at the Company. He received a Ph.D. in Physical
Chemistry/Computational Chemistry and a MSc in Physical
Chemistry/Biochemistry/Organic Chemistry from KTH Royal Institute of
Technology in Stockholm, Sweden. He currently serves on the board of the
Swedish National Committee for Chemistry and has been the recipient of
multiple awards for his studies and teaching.

About Proteostasis Therapeutics

Proteostasis Therapeutics is developing disease-modifying therapeutics for
orphan and neurodegenerative diseases. The Company’s lead programs in cystic
fibrosis (CF) and protein aggregation disorders such as Parkinson’s disease
modulate protein chaperone and proteasomal degradation pathways within the
cell. These pathways are part of the cellular ‘quality control’ machinery,
called the protein homeostasis network or Proteostasis Network (PN) that
regulates protein folding, trafficking, and clearance. By enhancing the
function and capacity of the PN, the Company’s product candidates correct for
imbalances in the PN resulting from the cumulative effects of disease, genetic
mutations, environmental factors, and aging. For more information, please


Stern Investor Relations, Inc.
Lilian Stern, 212-362-1200
Press spacebar to pause and continue. Press esc to stop.